Federal Register #Docket No. FDA-2022-N-0621

FDA Renews Advisory Committees for Anesthetic/Analgesic Drugs and COVID-19 Vaccines

This notice announces the renewal of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and a public meeting for the Vaccines and Related Biological Products Advisory Committee. - Government Buyer: - Food and Drug Administration (FDA), Department of Health and Human Services - OEMs and Vendors: - No OEMs or commercial vendors are mentioned; this is not a procurement for products or services - Products/Services Requested: - Renewal of the Anesthetic and Analgesic Drug Products Advisory Committee - Provides expert advice on anesthetics, analgesics, abuse-deterrent opioids, and related drug products - Public advisory committee meeting for the Vaccines and Related Biological Products Advisory Committee - Focused on recommendations for the 2026-2027 COVID-19 vaccine composition - Unique or Notable Requirements: - Committee members must have expertise in anesthesiology, analgesics, epidemiology, and related specialties - No product part numbers, quantities, or commercial procurement involved - Locations: - FDA Headquarters, Silver Spring, MD - FDA Dockets Management Staff, Rockville, MD

Description

The Food and Drug Administration (FDA) is announcing the renewal of the Anesthetic and Analgesic Drug Products Advisory Committee by the Commissioner of Food and Drugs. The committee's charter will be renewed for an additional 2 years beyond the current expiration date, extending until May 1, 2028. The committee provides expert advice on the safety and effectiveness of anesthetic and analgesic drug products, including opioids and novel analgesics. It consists of at least six voting members with expertise in anesthesiology, analgesics, epidemiology, and related specialties.

View original listing